Download

1 / 1

Effects of Dorsal Administration of DNCB on Skin Sensitization in Mice

Jan 11, 2025

10 likes | 84 Vues

This study investigates the impact of dorsal administration of 1% DNCB on skin sensitization in mice over 3, 7, and 15 weeks, along with 0.3% DNCB. Supplementary figure 1 provides additional insights.

Share Presentation

Embed Code

misu

Télécharger la présentation

Effects of Dorsal Administration of DNCB on Skin Sensitization in Mice

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Dorsal administration of 1% DNCB Oral / Dorsal administration of C6 8 3 7 Week s 0 1 5 6 2 4 Dorsal administration of 0.3% DNCB Supplementary figure 1

Supplementary figure 1

Supplementary figure 1. Supplementary figure 2 . sNF96.2. ST88-14. T265-2C. NF90.8. Supplementary figure 3. NF90.8. sNF96.2. T265-2C. ST88-14. Supplementary figure 4. A. B. NF90.8. siRNA mTOR#13. siRNA mTOR#19. siRNA GFP. mTOR. GAPDH. ST88-14. siRNA mTOR#13.

232 views • 12 slides

Supplementary Figure 1

Supplementary Figure 1. MW/1000. pH. SJIA. POLY. Others. F. FI. F. KD. Q. Q. C3. AGP1. ACT. SAP. SAA. S100A8. S100A9. HP. CRP. C9. C4. APO-IV. APO-L1. AMBP. KLKB1. VDB. CFH. ATIII. A2M. ATIII. APO-E. APO-D. FGG FGB. TTR. GSN. APOA1. Figure 1. 12. 10. 8.

203 views • 7 slides

Supplementary Figure 1

Supplementary Figure 1. A. B. C. Supplementary Figure 2. Supplementary Figure 3. A. PHTX-14B Day 10. B. MDA-MB-231 Day 10. Supplementary Figure 4. Vehicle. MLN8237 20mg/kg QDx3/wk. Treatment Period. 2500. 2000. 1500. Average Tumor Volume (mm^3). 1000. 500. 0. 0. 10. 20.

274 views • 5 slides

Supplementary Figure 1

Supplementary Figure 1. 3. 2,5. 2. 1,5. 1. 0,5. 0. 6. 5. 4. 3. 2. 1. 0. A. WT with FSK+Gen. WT with FSK. lF508del with FSK+Gen. lF508del with FSK. ns. ns. ns. ns. Bicarbonate secretion ( normalized to the rate in FSK-treated F508del as 1). 10 min post peak response.

138 views • 2 slides

Supplementary Figure 1

Supplementary Figure 1. a. b. c. a continuous schedule for 35 consecutive days. an intermittent schedule. DNA vaccination (50 ug/mouse). DNA vaccination (50 ug/mouse). A20 Lymphoma. A20 Lymphoma. Day. Day. 1. 35. 0. 14. 28. 0. 14. 28. 42. 21. 18. 35. 42. 32. 7. 4.

120 views • 3 slides

Supplementary Figure 1

a. *. *. ns. 3. 2. RANK Arbitrary Score. 1. 0. b. RANK. 1 2 3 4 5 6 7 8 9 10 11. Metastasis lymph node. Primary tumor. Normal breast. Supplementary Figure 1. Prolactin. RANKL. RANKL. pERK1/2. pERK1/2. pAKT. ERK1/2. AKT. b -Actin. pSTAT5. STAT5.

196 views • 7 slides

Supplementary Figure 1

Supplementary Figure 1. HM466934. I. II. pre-A. A. B. C. D/E. Supplementary Figure 2. V. IV. HM466934. HM466934. VI. HM466934. Supplementary Figure 3. HM466935. CDUV. Supplementary Figure 4. 34. MRMBV. MRCV. TUAV. ORXV. ALEV.

192 views • 4 slides

Supplementary Figure 1

IgVH unmutated. IgVH mutated. Low-risk. Intermediate-risk. High-risk. P14 cluster. N6 cluster. ZAP-70. CD38. IgVH status. Supplementary Figure 1.

105 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. CEPH: CYP2C8 (40kb, chr10:96782845..96822844). MAF=0.05. B. Hap-B. Hap-E. Hap-F. Haplotypes above 2%. Hap-A. Hap-D. Hap-C1+C2. Hap-C3. 3´UTR. CYP2C8. Pr. A. JPT+HCB: Asian. YRI: African. Supplementary Figure 2. A. B. C. A. B. C. Hap D (*3). Hap B.

235 views • 3 slides

Supplementary Figure 1

A. B. D. C. E. CD20. CagA. Merge. DAPI. Supplementary Figure 1.

185 views • 2 slides

Supplementary Figure 1

Nephrin. Nephrin. Nephrin. Nephrin. Nephrin. Synaptopodin. Synaptopodin. Synaptopodin. Synaptopodin. Synaptopodin. A. Merge. Merge. Merge. Merge. Merge. B. Podocin. Podocin. Podocin. Podocin. Podocin. Day 28. Control. Day 3. Day 15. Day 7. ADRN 11 mg/kg. Cont. Day3.

88 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. A. MIG (pMSCV-ires-GFP). I. GFP. LTR. LTR. MIG-PL2 (pMSCV-PLAGL2-ires-GFP). PL2. GFP. LTR. LTR. I. B. CBFb-MYH11 + HPs. GFP sort. Gene expression profile. Genes commonly deregulated in PL2+ cells. MIG-PL2 transduction. MIG transduction. GFP sort.

144 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. A. B. C.

91 views • 1 slides

Supplementary Figure 1.

MgrA. MepR. Supplementary Figure 1.

99 views • 1 slides

Supplementary Figure 1

90. 85. 80. 75. 70. 65. 40. 44. 48. 52. 56. 90. 80. 70. 60. 50. 38. 40. 42. 44. 46. 48. 50. 52. 90. 80. 70. 60. 50. 40. 30. 25. 30. 35. 40. 45. 50. 55. Normal. r = 0.043. p = 0.678. Methylation Level of LINE1 (%). Background. r = 0.063. p = 0.559.

126 views • 3 slides

Supplementary Figure 1

Supplementary Figure 1. Nominal p-value =0.0 FDR q-value= 0.19. Nominal p-value =0.004 FDR q-value= 0.30. Nominal p-value =0.013 FDR q-value= 0.19. Nominal p-value =0.033 FDR q-value= 0.18. Nominal p-value = 0.007 FDR q-value= 0.18. Nominal p-value =0.075 FDR q-value= 0.19.

131 views • 5 slides

Supplementary Figure 1

Supplementary Figure 1. Venkatachalam et al. 2013. ab. a. ab. abc. c. 24 48 72 96 120. Hours after FB17 treatment. Supplementary Figure 2. Venkatachalam et al. 2013. At1g11610. At3g28360. At1g21240. At3g14460. At3g20190. UBQ1.

157 views • 4 slides

Supplementary Figure 1

Supplementary Figure 1. Expansion of MSCs in 20% oxygen vs 5% oxygen. Supplementary Figure 2. Expansion of Kaneka-filtered cells in Flasks (P4) and the Quantum (P2). Supplementary Figure 3. Adipogenesis. Osteogenesis. Chondrogenesis.

276 views • 8 slides

Supplementary Figure 1

88 views • 2 slides

Supplementary Figure 1

Supplementary Figure 1. ***. 120000. 100000. ***. 80000. 60000. Relative light units (RLU). 40000. 20000. 0. Dox. +. -. +. -. Line I. Line 2. rtTA. rtTA. A. MMTV- rtTA TET0-PELP1 Line 1. MMTV- rtTA TET0-PELP1 Line 2. B. TetO-PELP1. MMTV- rtTA. WT. + Dox. T7-PELP1.

114 views • 1 slides

Supplementary Figure 1

A. *. A average weight [g]. A average weight [g]. CR. CR. Control. Control. T ime of experiment [week s ]. T ime of experiment [week s ]. *p&lt;0,05. B. Supplementary Figure 1.

88 views • 1 slides

Supplementary Figure 1.

92 views • 1 slides

More Related